Hence, little clinical data exists regarding β2-AR agonist administration within this context, with data derived from a few small, non-randomised studies in HF patients [45]–[46] and chronic lung disease patients with HF, receiving β2-AR agonist therapy [42], [47]. The gene discussed is ADRB2; the disease is chronic lung disease.